Patients with HBV, HCV, or Both in the IMbrave150 Trial

This article responds to your request for information on the use of Tecentriq® (atezolizumab) in patients with hepatitis B (HBV), or hepatitis C (HCV), or both. This article contains data from published and unpublished sources.

Download article Download

Last updated August 31, 2023


  • The Phase 3 IMbrave150 trial assessed the use of first-line Tecentriq in combination with Avastin versus sorafenib in patients with locally advanced or metastatic unresectable HCC.
    • HBV and HCV infection levels in patients were assessed at trial enrolment:
      • Patients were excluded from the IMbrave150 trial if they had both active HBV and active HCV.
        • Patients with active, controlled HBV were included in the trial, if HBV was treated and HBV DNA <500 IU/mL within 28 days of trial initiation.
          • Patients with active, controlled HCV infection were included in the trial.
            • Nucleoside / nucleotide analogues and antivirals were used in IMbrave150 to treat HBV and HCV in the trial.


            HBV= Hepatitis B virus

            HCC= Hepatocellular carcinoma

            HCV= Hepatitis C virus

            PCR= Polymerase chain reaction

            IMBrave150 trial overview

            IMbrave150 was a Phase 3, global, open-label, randomised study that evaluated the efficacy and safety of Tecentriq in combination with Avastin, versus sorafenib in 501 patients with locally advanced or metastatic unresectable HCC [1].

            Eligible patients had to have

            • no prior systemic therapy,
              • Child-Pugh A liver cirrhosis,
                • performance status of 0 or 1, and
                  • measurable disease per RECIST v1.1 not amendable to curative or locoregional therapies.

                    The IMBrave150 protocol provides a full list of additional inclusion and exclusion criteria [1].

                    Inclusion and exclusion criteria according to HBV and HCV status

                    Levels of HBV and HCV infection were assessed in patients at trial enrolment. Table 1 provides the inclusion and exclusion criteria for patients with HBV and HCV infection in the IMbrave150 trial.


                    Table 1. Inclusion and exclusion criteria in the IMbrave150 trial for patients wtih active HBV or HCV [1]

                    In patients had active HBV and active HCV then they were included in trial on the conditions

                    Patient characteristics at baseline

                    Table 2 provides data on the number of patients in the IMbrave150 trial who had HBV and HCV infection at baseline. As Table 1 shows, patients were not enroled to the trial if they had co-infection with both active HBV and active HCV.


                    Table 2. Patients receiving treatment for hepatitis in the IMbrave150 trial [2]

                    patients with Infections at baseline for HBV, Chronic HBV HCV and Chronic HCV in tecetriq and avastin and sorafenib

                    HBV and HCV medication

                    Table 3 provides data on the HBV and HCV medication administered to patients in the IMbrave150 trial.


                    Table 3. Number of patients with HBV and HCV infections in the IMbrave150 trial [2]

                    previous or concomitant Medication in Nucleoside , nucleotide analogues and Anti- virals for Tecentriq , Avastin and Sorafenib

                    Efficacy and safety stratified by HBV and HCV status

                    Subgroup analyses of IMbrave150 safety and efficacy data for HBV and HCV patients was not performed [2].


                    1. Finn R, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-1905.
                      1. Roche Internal Clinical Study Report (Accessed July 2023).

                        Welcome to Medically

                        The Roche Science Hub

                        This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                        Not a healthcare professional? Browse:

                        This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                        You are Leaving Medically

                        By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.